4.8 Article

Redox-Responsive Molecularly Imprinted Nanoparticles for Targeted Intracellular Delivery of Protein toward Cancer Therapy

期刊

ACS NANO
卷 15, 期 11, 页码 18214-18225

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.1c07166

关键词

sialic acid; molecular imprinting; cell recognition; drug delivery; cancer therapy

资金

  1. National Natural Science Foundation of China [21834003]
  2. National Key R&D Program of China [2018YFC0910301]
  3. Ministry of Science and Technology of China
  4. [ZYJH004]

向作者/读者索取更多资源

The study introduces a novel protein delivery strategy using sialic acid-imprinted biodegradable silica nanoparticles, showing targeted cancer therapy potential by effectively encapsulating cytotoxic protein RNase A. The nanovectors exhibited specific tumor-targeting ability and enhanced cell cytotoxicity, providing a promising platform for biomacromolecule delivery in cancer therapy.
Although protein therapeutics is of significance in therapeutic intervention of cancers, controlled delivery of therapeutic proteins still faces substantial challenges including susceptibility to degradation and denaturation and poor membrane permeability. Herein, we report a sialic acid (SA)-imprinted biodegradable silica nanoparticles (BS-NPs)-based protein delivery strategy for targeted cancer therapy. Cytotoxic ribonuclease A (RNase A) was effectively caged in the matrix of disulfide-hybridized silica NPs (encapsulation efficiency of similar to 64%), which were further functionalized with cancer targeting capability via surface imprinting with SA as imprinting template. Such nanovectors could not only maintain high stability in physiological conditions but also permit redox-triggered biodegradation for both concomitant release of the loaded therapeutic cargo and in vivo clearance. In vitro experiments confirmed that the SA-imprinted RNase A@BS-NPs could selectively target SA-overexpressed tumor cells, promote cells uptake, and subsequently be cleaved by intracellular glutathione (GSH), resulting in rapid release kinetics and enhanced cell cytotoxicity. In vivo experiments further confirmed that the SA-imprinted RNase A@BS-NPs had specific tumor-targeting ability and high therapeutic efficacy of RNase A in xenograft tumor model. Due to the specific targeting and traceless GSH-stimulated intracellular protein release, the SA-imprinted BS-NPs provided a promising platform for the delivery of biomacromolecules in cancer therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据